BMC Cancer

ERRATUM

Open Access

CrossMark

Erratum to: PNA clamping-assisted fluorescence melting curve analysis for detecting *EGFR* and *KRAS* mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer

Ji-Youn Han[1,3*], Jae-Jin Choi[2], Jin Young Kim[1], You Lim Han[1] and Geon Kook Lee[1]

Erratum

Unfortunately, the original version of this article [1] contained an error. Within Fig. 1, Fig. 1c and d were missing. The correct version of Fig. 1 can be found below and has been updated in the original article.

Author details
[1]Lung Cancer Branch, Research Institute, National Cancer Center, Goyang, Korea. [2]PANAGENE Inc., Daejeon, Korea. [3]Center for Lung Cancer, Hospital, National Cancer Center, 323 Ilsan-ro, Ilsan-dong-gu, Goyang, Gyeonggi 10408, Korea.

Reference
1. Han JY, et al. PNA clamping-assisted fluorescence melting curve analysis for detecting *EGFR* and *KRAS* mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer. BMC Cancer. 2016;16:627. doi:10.1186/s12885-016-2678-2.

* Correspondence: jymama@ncc.re.kr
[1]Lung Cancer Branch, Research Institute, National Cancer Center, Goyang, Korea
[3]Center for Lung Cancer, Hospital, National Cancer Center, 323 Ilsan-ro, Ilsan-dong-gu, Goyang, Gyeonggi 10408, Korea
Full list of author information is available at the end of the article

BioMed Central

Han *et al. BMC Cancer* (2016) 16:803

Page 2 of 2

Fig. 1 Schematic representation of EGFR and KRAS mutation detection using PANAMutyperTM: EGFR (**a**) and KRAS (**b**). Sensitivity of the EGFR L858R and E19del (**c**) and KRAS G12V and G12R (**d**) mutants according to their cellularity by diluting to 100, 10, 1, 0.1, 0.01, 0 % with respect to the wild cell line DNA and mutant cell line DNA. The data presented here are representative obtained from sensitivity test conducted more than 50 times. MT, mutant type